Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881661 | 0.81 | HTR2A (0.49) | HTR2AHTR2CSLC6A2SLC6A4FABP4 | |
| SCHEMBL264536 | 0.79 | GRM2 (0.36) | HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL25141967 | 0.79 | NOTUM (0.46) | HTR2AHTR2CSLC6A2SLC6A4NR3C2 | |
| SCHEMBL1956177 | 0.79 | HTR2C (0.43) | HTR2AHTR2C | |
| SCHEMBL17429459 | 0.77 | HTR2A (0.52) | HTR2AHTR2C | |
| SCHEMBL13552249 | 0.77 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL3710160 | 0.73 | — | — | |
| SCHEMBL15155115 | 0.73 | HTR2A (0.32) | HTR2AHTR2C | |
| SCHEMBL3928563 | 0.73 | JAK2 (0.33) | — | |
| SCHEMBL18305541 | 0.73 | HTR2A (0.54) | HTR2AHTR2CRHEBSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-107072985-B | Therapeutic inhibiting compounds | 莱福斯希医药公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| US-10259803-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-16 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | disclosed |
| WO-2010093191-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
| US-10266515-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
| US-10259803-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | HTR2A 3554/4885HTR2C 3898/4885RHEB 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.